2022
DOI: 10.3390/curroncol29030113
|View full text |Cite
|
Sign up to set email alerts
|

Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support Cancer Care

Abstract: Biomarker data are critical to the delivery of precision cancer care. The average turnaround of next-generation sequencing (NGS) reports is over 2 weeks, and in-house availability is typically limited to academic centers. Lengthy turnaround times for biomarkers can adversely affect outcomes. Traditional workflows involve moving specimens through multiple facilities. This study evaluates the feasibility of rapid comprehensive NGS using the Genexus integrated sequencer and a novel streamlined workflow in a commu… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
18
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 33 publications
(24 citation statements)
references
References 17 publications
1
18
0
Order By: Relevance
“… 72 As a consequence, the use of NGS for the pre‐emptive guidance of personalized prescribing is not realistic for acute cases. Notably however, substantially faster turnaround times down to three business days have recently been reported for NGS‐based testing of molecular panels in a community hospital setting, 73 raising hopes that application for sub‐acute cases might become realistic in the near future. It is important to emphasize that once a pharmacogenomic profile is generated for a given patient, this information will be rapidly available for future occasions, meaning potential access even on an acute basis.…”
Section: Implementation and Precision Medicinementioning
confidence: 99%
“… 72 As a consequence, the use of NGS for the pre‐emptive guidance of personalized prescribing is not realistic for acute cases. Notably however, substantially faster turnaround times down to three business days have recently been reported for NGS‐based testing of molecular panels in a community hospital setting, 73 raising hopes that application for sub‐acute cases might become realistic in the near future. It is important to emphasize that once a pharmacogenomic profile is generated for a given patient, this information will be rapidly available for future occasions, meaning potential access even on an acute basis.…”
Section: Implementation and Precision Medicinementioning
confidence: 99%
“…In cases where benchmarks are not met, strategies to improve turnaround time should be considered, which may include reflexive testing for all new CRC diagnoses, adjustments to workflow, and/or implementation of rapid biomarker testing methods. 8 , 173 …”
Section: Biomarker Testing Methodologies and Reportingmentioning
confidence: 99%
“…In cases where benchmarks are not met, strategies to improve turnaround time should be considered, which may include reflexive testing for all new CRC diagnoses, adjustments to workflow, and/or implementation of rapid biomarker testing methods. 8,173 Reporting of biomarker testing results should conform to existing guidelines (American College of Medical Genetics, College of American Pathologists). 174,175 Stating the testing method used, including details of which genomic alterations can be detected and the limitations of the test, is important as biomarker standards evolve over time.…”
Section: Turnaround Time and Reportingmentioning
confidence: 99%
“…9 Genexus NGS v1 uses targeted amplicon-based NGS and an Ion Torrent integrated sequencer to detect single nucleotide variants, indels, copy number variants, and gene fusions in genomic DNA and RNA from select regions across 50 genes using the Oncomine Precision Assay. 10…”
Section: Molecular Analysismentioning
confidence: 99%